Clinical Trial Update: Ibrutinib and PD-1 Blockade in High Risk Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib and a PD-1 blockade in high-risk chronic lymphocytic leukemia has been terminated, with results posted on …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Ibrutinib (ibrutinib)
• PD-1 blockade

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2023-09-25